Home > Healthcare > Pharmaceuticals > Finished Drug Form > Orthobiologics Market

Orthobiologics Market Analysis

  • Report ID: GMI9311
  • Published Date: Apr 2024
  • Report Format: PDF

Orthobiologics Market Analysis

Based on product type, the market is categorized into viscosupplementation products, demineralized bone matrices, synthetic orthobiologics, bone morphogenic protein, allografts, platelet-rich plasma (PRP), and other product types. The viscosupplementation products segment witnessed the largest revenue and was valued at USD 2 billion in 2023.

  • Viscosupplementation products have a favorable safety profile, with minimal risk of adverse effects or complications. This makes them suitable for a wide range of patients, including those who may not be candidates for surgery or are seeking alternatives to pain medications.
  • Additionally, viscosupplementation has become a widely accepted and preferred treatment option for osteoarthritis, especially in the knee joint. These products consist of hyaluronic acid, a natural component of synovial fluid, which helps lubricate and cushion the joints, providing pain relief and improving joint function, hence may contribute to the segmental growth.

Based on application, the orthobiologics market is categorized into spinal fusion, soft-tissue injuries, osteoarthritis and degenerative arthritis, and other applications. The osteoarthritis and degenerative arthritis segment dominated the market, with the revenue of around USD 2.8 billion revenue in 2023.

  • Patients seek treatment options that provide long-term relief and improve joint function, making orthobiologics an attractive option due to their regenerative properties and potential to address underlying joint damage caused due to osteoarthritis.
  • Clinical studies have demonstrated the effectiveness of orthobiologics in managing symptoms and improving function in patients with osteoarthritis and degenerative arthritis. Positive outcomes, such as pain reduction, improved joint mobility, and preservation of joint structure, contribute to the dominance of these segments in the market.
Orthobiologics Market, by End-use (2023)

Based on end-use, the orthobiologics market is categorized into hospitals and orthopedic clinics, ambulatory surgical centers, research and academic institutes, and other end-users. The hospitals and orthopedic clinics segment held the dominant position in the market and is anticipated to reach around USD 7.6 billion in 2032.

  • Hospitals and orthopedic clinics offer comprehensive treatment facilities for a wide range of musculoskeletal conditions, including fractures, joint injuries, and degenerative diseases. These facilities often have specialized orthopedic departments with experienced surgeons and access to advanced diagnostic tools, making them the primary choice for patients seeking orthobiologic treatments.
  • Moreover, hospitals and orthopedic clinics employ orthopedic surgeons who specialize in orthobiologic procedures and the handling of related devices like joint reconstruction devices, spinal fusion devices, and soft tissue repair. These surgeons have the expertise and experience to perform complex orthopedic surgeries and administer orthobiologic therapies effectively.
North America Orthobiologics Market, 2021- 2032 (USD Billion)

North America orthobiologics market accounted for USD 3 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

  • North America has a significant number of individuals participating in sports and physical activities, leading to a higher incidence of sports-related injuries. orthobiologics, such as platelet-rich plasma (PRP) and stem cell therapies, are increasingly being used to accelerate the healing process and facilitate recovery from these injuries.
  • For instance, a report published by the CDC in 2021 indicated that approximately 8.6 million sports and recreation-related injuries were treated in the U.S. emergency departments annually between 2016 and 2019. These data represents the importance of orthobiologics in the field of sport injury.

U.S. Orthobiologics market held a dominant position with the market share of around 93% in 2023.  

  • Ongoing research and technological advancements have led to the development of new orthobiologic products with improved efficacy and safety profiles. This has increased confidence among healthcare providers and patients, driving demand for these treatments.
  • Additionally, patients in the U.S. are increasingly seeking minimally invasive treatment options that offer faster recovery times and fewer complications compared to traditional surgeries. Orthobiologics provide an alternative to invasive procedures, anticipating their increased demand.

UK orthobiologics market is anticipated to witness notable growth during 2024-2032.

  • There is growing awareness among healthcare professionals and patients in the UK about the benefits of orthobiologics for managing musculoskeletal conditions. This increased awareness, coupled with positive clinical outcomes, has led to greater acceptance and utilization of orthobiologic treatments in the country.
  • Furthermore, a survey conducted by the National Institute for Health and Care Excellence (NICE) in 2021 found that a majority of patients are open to trying regenerative therapies if recommended by their healthcare provider. This indicated a growing acceptance of orthobiologics among patients in the UK.

China may experience a high growth potential in the orthobiologics market.

  • Rising disposable incomes and healthcare spending in China have led to greater demand for advanced medical treatments, including orthobiologics. Patients are increasingly willing to invest in treatments that offer superior outcomes and quality of life.
  • For instance, as per the report by National Bureau of Statistics of China in 2021, indicates the approximately 1.3 trillion USD healthcare spending in 2020, representing a year-on-year growth of 11.8%. This significant increase in healthcare spending reflects the country's ongoing efforts to improve healthcare infrastructure, expand access to medical services, and invest in advanced medical treatments, including orthobiologics.  

Japan orthobiologics market is anticipated to witness significant growth during the forecast period.

  • The Japanese government has implemented supportive reimbursement policies for orthobiologic treatments, making them more accessible and affordable for patients. This encourages healthcare providers to offer these therapies and contributes to market growth.
  • For instance, Japan government has implemented favorable reimbursement policies for regenerative medicine, including orthobiologic treatments. One recent state to demonstrate this is the introduction of the "Regenerative Medicine Product Reimbursement System" in April 2020. These efforts by the government contributes to the rising market growth.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Orthobiologics market size was valued at USD 6.8 billion in 2023 and is estimated to grow at 5.7% CAGR from 2024 to 2032, driven by the increasing prevalence of orthopedic disorders.

The hospitals and orthopedic clinics segment in the orthobiologics industry will generate USD 7.6 billion by 2032, due to the strong need for handling joint reconstruction devices, spinal fusion devices, and soft tissue repair.

North America orthobiologics market size accounted for USD 3 billion in revenue in 2023, owing to the prevalence of individuals participating in sports and physical activities and higher incidence of sports-related injuries.

Anika Therapeutics, Inc., Arthrex Inc., Bioventus LLC, Depuy Synthes (JnJ), Globus Medical Inc., Medtronic PLC, NuVasive Inc., Orthofix Medical Inc., RTI Surgical, Seaspine Holdings Corporation, Stryker Corporation and Zimmer Biomet

Orthobiologics Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 149
  • Countries covered: 23
  • Pages: 100
 Download Free Sample